ZEPOSIA (Celgene Pty Ltd)
Product name
ZEPOSIA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
218 working days (255)
Active ingredients
ozanimod hydrochloride
Registration type
NCE/NBE
Indication
ZEPOSIA (capsule) is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis.